Sign In
Buy AVRO
$1.40
+0 (+0%)
At Close: Sep 19, 2024
Why Moderna, Avrobio, And More Are Moving Today
12:23pm, Monday, 08'th Feb 2021
Moderna (NASDAQ: MRNA) shares are trading higher amid South Africa stopping distribution of the AstraZeneca COVID-19 vaccine due to ineffectiveness in treating a disease variant. Moderna is working on
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
08:07am, Monday, 08'th Feb 2021
Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction,
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
07:00am, Friday, 22'nd Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announce
AVROBIO to Present at the ICR Conference 2021
07:00am, Friday, 08'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
Avrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 Catalysts
05:01am, Saturday, 26'th Dec 2020
AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipe
AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
10:00am, Friday, 25'th Dec 2020
AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise.
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 04'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
10:06pm, Thursday, 19'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 sh
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 06'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
Online Investment Platform Offering Shares Of 1937 Heisman Trophy, Other Sports Memorabilia
12:00am, Friday, 16'th Oct 2020
The 1937 Heisman Trophy is being offered via Rally Rd., an online investment platform. Any U.S. adult with a Social Security number and bank account can buy shares for $46 apiece.
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
12:00am, Monday, 05'th Oct 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
Protalix Could Claim Substantial Global Market Share In Fabry Disease (NYSEMKT:PLX)
06:54am, Thursday, 01'st Oct 2020
Strong need for improved enzyme replacement therapies. Protalix's deliberately engineered ERT appears to fill this unmet need.
